ANDA 212277, held by Annora Pharma. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 212277 (Venlafaxine Hydrochloride), held by Annora Pharma, was first approved by FDA on Jul 8, 2019, with 3 approved supplements and 0 published complete response letters.
Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 8, 2019 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Mar 19, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 19, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 19, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 8, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters